Application for production of raw and auxiliary materials of atosiban passed the audit

this year On September 16, the enterprise gutuo Biotechnology Co., Ltd. (gutuo Biotechnology Co., Ltd.) learned from the "information disclosure service platform for application for registration of raw and auxiliary materials, pharmaceutical excipients and drug packaging materials" of the drug evaluation center of the State Food and drug administration that the company had changed the collaborative evaluation results of the raw and auxiliary materials (trial number: cyhs1500366) and traditional Chinese medicine preparations submitted by the company to the drug evaluation center of the State Drug Administration In the sale of traditional Chinese medicine preparations.

As a synergetic receptor antagonist of vasopressin V1a and oxytocin V1a, atosiban has high aspect ratio affinity with protein kinase in chemical structure. According to the competitive fusion with oxytocin and vasopressin V1a protein kinase, it blocks the efficacy of oxytocin and vasopressin, and reduces uterine contraction. Atrosiban injection is critical in clinical medicine to slow down the birth of premature infants.

The sale of atosiban acetate​, a new raw material and auxiliary material, has promoted the influence of the upstream and downstream raw materials and excipients of gutuo biological Co., Ltd., and enriched the variety of products. However, due to the damage of marketing environment and other factors, the operation status of the commodity is changeable.

If the original article is reprinted, please indicate the source（ www.gotopbio.com ）”